Community-Acquired Pneumonia (CAP)
12
2
3
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 29/100
8.3%
1 terminated out of 12 trials
83.3%
-3.2% vs benchmark
33%
4 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms
A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older
Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia
Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care
Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR
How Does Medical Clown Intervention Affect the Length of Hospitalization in Children With Pneumonia
Clinical Trial of Fei Re Qing Granules in the Treatment of Elderly Community-Acquired Pneumonia
Clinical Impact of Rapid Molecular Testing for Pathogens in Patients With Severe Acute Respiratory Illness : A Pragmatic Trial
Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
Efficacy of High Doses Penicillin V Versus High Doses Amoxicillin in the Treatment of Non-severe Pneumonia.
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia